Bayer AG has high hopes to be a key player as next generation immuno-oncology candidates approach the market; successfully launching larotrectinib as soon as possible with its partner Loxo Oncology Inc. is a first major test for Bayer's IO outlook.
The German big pharma is also looking for external development candidates to supplement its pipeline as its key growth products,...






